Les hypo-lipidémiants : Des propriétés nouvelles au fil des années, les statines et les fibrates révèlent de nouvelles propriétés. Dans le domaine de l'hta, de nouvelles études s'attachent plus précisément à en cerner les conséquences = Antilipemic agentHAÏAT, Robert.Concours médical (Paris). 2001, Vol 123, Num 10, pp 24-26, issn 0010-5309, SUPConference Paper

Mode d'action moléculaire des fibrates = Molecular mechanism of action of fibratesFRUCHART, J.-C; DURIEZ, P; STAELS, B et al.Journal de la Société de biologie. 1999, Vol 193, Num 1, pp 67-75, issn 1295-0661Article

Fenofibrate-induced photosensitivityLEENUTAPHONG, V; MANUSKIATTI, W.Journal of the American Academy of Dermatology. 1996, Vol 35, Num 5, pp 775-777, issn 0190-9622, 1Article

Pharmacokinetic interactions between statins and fibratesCORSINI, Alberto; BELLOSTA, Stefano; DAVIDSON, Michael H et al.The American journal of cardiology. 2005, Vol 96, Num 9A, pp 44K-49K, issn 0002-9149, SUPConference Paper

Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humansPERREAULT, Leigh; BERGMAN, Bryan C; HUNERDOSSE, Devon M et al.Metabolism, clinical and experimental. 2011, Vol 60, Num 8, pp 1107-1114, issn 0026-0495, 8 p.Article

Paradoxical Decrease in High-Density Lipoprotein Cholesterol with Fenofibrate: A Ouite Rare Phenomenon IndeedMOMBELLI, Giuliana; PAZZUCCONI, Franco; BONDIOLI, Alighiero et al.Cardiovascular therapeutics (Print). 2010, Vol 28, Num 3, pp 153-160, issn 1755-5914, 8 p.Article

Effect of Clofibrate in Non-hemolytic Indirect Hyperbilirubinemia in Full Term NeonatesEGHBALIAN, Fatemeh; POURHOSSEIN, Abolfazl; ZANDEVAKILI, Hassan et al.Indian journal of pediatrics. 2007, Vol 74, Num 11, pp 1003-1006, issn 0019-5456, 4 p.Article

A metabonomics study of the hepatotoxicants galactosamine, methylene dianiline and clofibrate in ratsISHIHARA, Kenji; KATSUTANI, Naruo; AOKI, Toyohiko et al.Basic & clinical pharmacology & toxicology (Print). 2006, Vol 99, Num 3, pp 251-260, issn 1742-7835, 10 p.Article

Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns : Application for quantitation in pharmaceutical formulationsMISZTAL, Genowefa; KOMSTA, Łukasz.Journal of AOAC International. 2005, Vol 88, Num 2, pp 479-489, issn 1060-3271, 11 p.Article

Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitroGRILLO, Mark P; BENET, Leslie Z.Drug metabolism and disposition. 2002, Vol 30, Num 1, pp 55-62, issn 0090-9556Article

Inhibitory effect of fenofibrate on neointima hyperplasia via G₀/G₁ arrest of cell proliferationLEE, Jung-Jin; YU, Ji-Yeon; ZHANG, Wei-Yun et al.European journal of pharmacology. 2011, Vol 650, Num 1, pp 342-349, issn 0014-2999, 8 p.Article

Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in HumansHONKALAMMI, J; NIEMI, M; NEUVONEN, P. J et al.Clinical pharmacology and therapeutics. 2011, Vol 89, Num 4, pp 579-586, issn 0009-9236, 8 p.Article

Use of Fibrates in the United States and CanadaJACKEVICIUS, Cynthia A; TU, Jack V; ROSS, Joseph S et al.JAMA, the journal of the American Medical Association. 2011, Vol 305, Num 12, pp 1217-1224, issn 0098-7484, 8 p.Article

Traiter la dyslipidémie du diabétique de type 2: place des fibratesHERMANS, M. P.Louvain médical. 2011, Vol 130, Num 3, issn 0024-6956, S31-S35Conference Paper

Fibrate-Associated Adverse Effects Beyond Muscle and Liver ToxicityFLORENTIN, M; LIBEROPOULOS, E. N; MIKHAILIDIS, D. P et al.Current pharmaceutical design. 2008, Vol 14, Num 6, pp 574-587, issn 1381-6128, 14 p.Article

Fenofibrate-induced cirrhosisAHMED, Furqaan; PETROVIC, Lydia; ROSEN, Ellen et al.Digestive diseases and sciences. 2005, Vol 50, Num 2, pp 312-313, issn 0163-2116, 2 p.Article

Gemfibrozil metabolite inhibits in vitro low-density lipoprotein (LDL) oxidation and diminishes cytotoxicity induced by oxidized LDLKAWAMURA, M; MIYAZAKI, S; TERAMOTO, T et al.Metabolism, clinical and experimental. 2000, Vol 49, Num 4, pp 479-485, issn 0026-0495Article

Profile of Serum Bile Acids in Noncholestatic Volunteers: Gender-Related Differences in Response to FenofibrateTROTTIER, J; CARON, P; STRAKA, R. J et al.Clinical pharmacology and therapeutics. 2011, Vol 90, Num 2, pp 279-286, issn 0009-9236, 8 p.Article

Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cellsARAKI, Hiromitsu; TAMADA, Yoshinori; TOMIYASU, Yuki et al.Angiogenesis (London). 2009, Vol 12, Num 3, pp 221-229, issn 0969-6970, 9 p.Article

Rhabdomyolyse induite par le fénofibrate en monothérapie = Rhabdomyolysis induced by fenofibrate monotherapyARCHAMBEAUD-MOUVEROUX, F; LOPEZ, S; COMBES, C et al.La Revue de médecine interne (Paris). 2006, Vol 27, Num 7, pp 573-574, issn 0248-8663, 2 p.Article

Les anticholestérolémiants, nouvelles approches thérapeutiques = Anti-cholesterol agents, new therapeutic approachesFRUCHART, J.-C; DURIEZ, P.Annales pharmaceutiques françaises. 2004, Vol 62, Num 1, pp 3-18, issn 0003-4509, 16 p.Article

Fabrication of a uniformly sized fenofibrate microemulsion by membrane emulsificationPRADHAN, Roshan; DONG WON LEE; CHOI, Han-Gon et al.Journal of microencapsulation. 2013, Vol 30, Num 1, pp 42-48, issn 0265-2048, 7 p.Article

Fenofibrate ― A Potential Systemic Treatment for Diabetic Retinopathy?TIEN YIN WONG; SIMO, Rafael; MITCHELL, Paul et al.American journal of ophthalmology. 2012, Vol 154, Num 1, pp 6-12, issn 0002-9394, 7 p.Article

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple DosesHONKALAMMI, J; NIEMI, M; NEUVONEN, P. J et al.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 5, pp 846-855, issn 0009-9236, 10 p.Article

Gemfibrozil-Induced Myositis in a Patient with Normal Renal FunctionHAHN, Martin; SRIHARAN, Kalavally; MCFARLAND, M. Shawn et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 1, pp 211-214, issn 1060-0280, 4 p.Article